April 16, 2018 / 9:10 PM / 6 days ago

BRIEF-Janssen Collaborates With Bristol-Myers Squibb To Develop & Commercialize Factor XIa Inhibitors

April 16 (Reuters) - Janssen Pharmaceutical Companies:

* JANSSEN ANNOUNCES WORLDWIDE DEVELOPMENT & COMMERCIALIZATION COLLABORATION WITH BRISTOL-MYERS TO ADVANCE THERAPY FOR CARDIOVASCULAR DISEASES

* THE JANSSEN PHARMACEUTICAL COMPANIES - ENTERED WORLDWIDE COLLABORATION WITH BRISTOL-MYERS TO DEVELOP, COMMERCIALIZE FACTOR XIA INHIBITORS

* JANSSEN - UNDER AGREEMENT, CO, BRISTOL-MYERS SQUIBB TO ADVANCE BMS-986177 INTO PHASE 2 CLINICAL TRIALS

* JANSSEN - COS TO SHARE DEVELOPMENT COSTS, COMMERCIAL PROFITS AND LOSSES; ADDITIONAL TERMS OF AGREEMENT NOT DISCLOSED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below